Dr. Garheng Kong is currently the Founder and Managing Partner of HealthQuest Capital, which he founded in 2013 as a Managing Partner at Sofinnova Ventures.  Dr. Kong joined Sofinnova Ventures in 2010 as a General Partner to focus on life science investments. A physician and engineer by training, Dr. Kong has 16 years of experience investing in innovative healthcare companies with a long list of successes. For the previous 10 years, he was at Intersouth Partners, most recently as a General Partner. During this time he served as the founding investor and Chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline) and lead investor of the first financing for Alimera Sciences (Nasdaq: ALIM). He has also led or been significantly involved with the investments of Cempra Pharmaceuticals (Nasdaq: CEMP, Chairman), Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation, TransEnterix, Calibra Medical (Acquired by Jonshon & Johnson), CancerGuide Diagnostics, Aldagen (Acquired by Cytomedix) and nContact Surgical. Dr. Kong currently serves on the boards of portfolio companies including Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, and Histogenics (HSGX).

Dr. Garheng Kong is currently the Founder and Managing Partner of HealthQuest Capital, which he founded in 2013 as a Managing Partner at Sofinnova Ventures.  Dr. Kong joined Sofinnova Ventures in 2010 as a General Partner to focus on life science investments. A physician and engineer by training, Dr. Kong has 16 years of experience investing in innovative healthcare companies with a long list of successes. For the previous 10 years, he was at Intersouth Partners, most recently as a General Partner. During this time he served as the founding investor and Chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline) and lead investor of the first financing for Alimera Sciences (Nasdaq: ALIM). He has also led or been significantly involved with the investments of Cempra Pharmaceuticals (Nasdaq: CEMP, Chairman), Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation, TransEnterix, Calibra Medical (Acquired by Jonshon & Johnson), CancerGuide Diagnostics, Aldagen (Acquired by Cytomedix) and nContact Surgical. Dr. Kong currently serves on the boards of portfolio companies including Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, and Histogenics (HSGX).